Alyeska Investment Group L.P. Buys 89,057 Shares of Repligen Corporation $RGEN

Key Points

• Alyeska Investment Group L.P. increased its stake in Repligen Corporation by 24.0%, owning approximately 0.82% of the company, worth $58.56 million after acquiring an additional 89,057 shares.
• Insider transactions included Director Martin D. Madaus purchasing 1,800 shares at an average price of $112.13, marking a significant increase in his position.
• Repligen's stock has seen mixed analyst ratings with a consensus rating of "Moderate Buy" and a target price ranging from $130.00 to $205.00 among various analysts.

Alyeska Investment Group L.P. lifted its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 24.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 460,237 shares of the biotechnology company's stock after purchasing an additional 89,057 shares during the quarter. Alyeska Investment Group L.P. owned 0.82% of Repligen worth $58,561,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Alliance Wealth Advisors LLC UT grew its stake in shares of Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after purchasing an additional 89 shares in the last quarter. State of Michigan Retirement System grew its stake in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after purchasing an additional 100 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after purchasing an additional 100 shares in the last quarter. State of Wyoming grew its stake in shares of Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock worth $297,000 after purchasing an additional 115 shares in the last quarter. Finally, Signaturefd LLC grew its stake in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Repligen Stock Up 3.3%

Shares of RGEN traded up $3.98 during midday trading on Friday, reaching $124.56. 1,043,994 shares of the stock were exchanged, compared to its average volume of 653,843. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The firm has a 50 day simple moving average of $121.53 and a 200-day simple moving average of $129.29. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.01 billion, a price-to-earnings ratio of -498.22, a P/E/G ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. During the same period last year, the business earned $0.40 earnings per share. The firm's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director owned 1,800 shares of the company's stock, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on RGEN shares. Evercore ISI decreased their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Tuesday. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Finally, Stephens raised Repligen to an "overweight" rating and set a $160.00 target price for the company in a research note on Tuesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $169.55.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.